Market Report: Persimmon slumps amid sector nervousness
Tuesday 08 January 2008
Shares in housebuilders dived yesterday on fears of fresh skeletons in upcoming trading statements. The performance of some of the biggest stocks in the business left no doubt about the extent of market nervousness regarding the prospect of more bad news from an already depressed sector.
Advice from Dresdner Kleinwort, to "abandon the sector ahead of this week's flurry of bad headlines", did not help investor sentiment as Persimmon, which will be the first to update the market tomorrow, slumped by 5.52 per cent, or 40p, to close at 685p. In the FTSE 250, Bovis, which is due to issues its update this Friday, fell by 5.76 per cent, or 33p, to close at 540p while Bellway lost almost 5 per cent, or 38p, to close at 734.5p.
Retail stocks also suffered, finding themselves stirred, shaken and pushed to the bottom of the table, as the market anticipated a visit from the ghost of the Christmas just past on the occasion of Marks & Spencer's trading statement, which is due tomorrow.
After being anointed Goldman Sach's "Christmas winner", M&S's prospects came into question in the weekend press. Predictions for like-for-like sales growth, which had hovered around +3 per cent, were reported to have been revised down to as low as -2 per cent. And while some were more charitable and pegged the numbers to come in flat, the speculation shaved almost 4 per cent off the stock as it ended the day down 19.5p at 498.5p.
M&S's sector counterpart Next lost 68p or 4.64 per cent, closing at 1,396p, while the B&Q owner Kingfisher lost 6.5p, or 5 per cent, closing at 123.5p. The three were part of the retail contingent in the table of the biggest losers on the FTSE 100. The blue-chip index shed 0.2 per cent, closing 12.8 lower at 6,335.7.
DSG International, which topped the list of fallers on the FTSE 250, closed down 6.25p, or 8.12 per cent, at 70.75p. Debenhams was just a few steps behind, coming eighth in the list, down almost 6 per cent, or 4.5p, at 71.25p.
The supermarket giant Sainsbury's, another venerable high-street name, saw its shares pulled down by news that it may have missed its internal sales and profits targets in the run-up to the crucial Christmas trading period. The company's share price dived 3.58 per cent, or 14.5p, to close at 391p.
Of the risers, British Energy swung to the top of the FTSE 100 leader board as analysts at Cazenove upgraded their estimates for the stock. The broker is reported to have changed its fair-value estimate for the shares to 730p from 660p on the back of higher long-term electricity prices, sending the share price up by 32.5p, or more than 6 per cent, to 571p.
Defensive stocks from the drug sector joined British Energy. GlaxoSmithKline rose by 3.53 per cent, or 45p, to close at 1,321p, the second highest riser on the 100 index yesterday, while AstraZeneca climbed 60p, or 2.84 per cent, to 2,170p, making it the fourth-best performing stock on the FTSE 100.
Scottish and Southern was another winner. The company's share price rose by more than 2 per cent, or 33p, to close at 1,668p as Credit Suisse said that its acquisition of the wind developer Airtricity made "solid strategic sense". While noting that the deal would bring more business and credit risk, the broker said that it would provide the company with new growth opportunities in international markets such as China.
Of the small caps, GCap Media saw its shares climb as the company confirmed that it had rejected a 300m-plus takeover bid from Global Radio. The rebuff propelled the commercial radio operator to the top end of the table of risers, with its shares jumping 45.45 per cent, or 55p, to close at 176p.
Huddersfield-based Marshalls saw its shares rise on the back of an upbeat trading statement. The company said that the public sector and commercial market, both important sales generators, had improved, sending its share price up by 17.5p or 6.4 per cent, to 254.25p.
And finally, after delaying its debut last month, Lifeline Scientific started trading on AIM. The specialist medical technology company raised 5.4m at a price of 150p per share. The company is focused on the Lifeport Kidney Transporter, a device which, Lifeline claims, improves the utilisation of donated kidneys and increases the organ recovery rate. By the day's close, the company shares had edged up slightly to close at 151.5p.
- 1 Finland schools: Subjects scrapped and replaced with 'topics' as country reforms its education system
- 2 The West has it totally wrong on Lee Kuan Yew
- 3 #FreeTheNipple: Women in Iceland bare breasts in solidarity with trolled student
- 4 Scientists have discovered a simple way to cook rice that dramatically cuts the calories
- 5 Zayn Malik quits One Direction: Hundreds of workers request compassionate leave following band member's exit
Germanwings captain Patrick Sondenheimer tried to break into locked cockpit door 'with an axe' as plane was descending
Amanda Knox murder conviction: Italian court overturns verdict for US student and Raffaele Sollecito in the killing of Meredith Kercher
Saudi Arabia says it won't rule out building nuclear weapons
The battle for the Middle East's future begins in Yemen as Saudi Arabia jumps into the abyss
#FreeTheNipple: Women in Iceland bare breasts in solidarity with trolled student
Nigel Farage brands LGBT activists 'filth' and 'scum' and accuses them of scaring away his children after they invade his local pub
Ukip supporters are 55 or older, white and socially conservative, finds British Social Attitudes Report
JK Rowling responds to fan tweeting she 'can't see' Dumbledore being gay
Russia threatens Denmark with nuclear weapons if it tries to join Nato defence shield
Jeremy Clarkson sacked live: Alan Yentob 'wouldn't rule out' ex Top Gear host's BBC return
Germanwings plane crash live: Co-pilot Andreas Lubitz wanted to 'do something people would remember him for'
iJobs Money & Business
Negotiable: Recruitment Genius: To provide a prompt, friendly and efficient se...
Negotiable: Recruitment Genius: You will be the first point of contact for all...
£18000 - £24000 per annum + benefits: Ashdown Group: HR, Payroll & Benefits Of...
£35000 - £38000 per annum + benefits : Ashdown Group: A highly successful, int...